ArticlePloS one2025
Identification and validation of diagnostic markers of atherosclerosis progression via bioinformatics strategies.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundArteriosclerosis (AS) is a leading cause of cardiovascular disease, imposing significant burdens on families and society. However, the underlying mechanisms remain unclear. This study aims to elucidate these mechanisms and explore potential pharmacological treatments through the integration of bioinformatics.
methodsThe GSE28829 dataset was retrieved from the GEO database. Differential gene expression between early- and late-stage AS plaques in GSE28829 was identified via the limma package. We focused on the intersecting genes associated with endoplasmic reticulum stress and mitochondrial damage. LASSO regression analysis was applied to pinpoint potential core genes associated with AS. An protein interaction network was constructed, with a focus on the hub genes within this network. Assessment of immune cell infiltration levels was achieved via the ssGSEA method and confirmed via CIBERSORT. We used the DrugBank database to predict small molecule drugs that could intervene in AS progression.
resultsIn this study, DEGs associated with AS were identified, and hub genes, including FCGR3A, ITGB2, TYROBP, FCGR2B, CTSS, FCER1G, CD86, TLR2, C1QB, and C1QA, were identified. We also found a strong correlation between the hub genes and immune processes, indicating that ER stress and mitochondrial damage were correlated with the activation of immune processes. Additionally, a diagnostic model for AS was established, demonstrating the substantial predictive value of these hub genes.
conclusionsThis study reveals the involvement of genes related to endoplasmic reticulum stress and mitochondrial damage in the pathogenesis of AS. These hub genes offer new directions for further research and the development of pharmacological treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.